We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Lab-on-a-Chip Infection Test Provides Cheaper, Faster Portable Diagnostics

By LabMedica International staff writers
Posted on 15 Dec 2020
Rapid screening and low-cost diagnosis play a crucial role in choosing the correct course of intervention when dealing with highly infectious pathogens. More...
This is especially important if the disease-causing agent has no effective treatment.

Despite low-cost onsite testing for infectious diseases being the holy grail of nucleic acid (NA) diagnostics, there are still no inexpensive and handheld solutions in the market that can provide truly portable, rapid NA amplification and detection.

Bioengineers at the Imperial College London (London, UK) developed a disposable, ultra-low-cost integrated silicon-based point-of-need (PoN) tri-modal NA transducer, known as TriSilix, that can chemically amplify and electrochemically detect pathogen-specific sequences of NA quantitatively in real-time. The developed chip, is a 'micro laboratory' which performs a miniature version of the polymerase chain reaction (PCR) on the spot. PCR is the gold-standard test for detecting viruses and bacteria in biological samples such as bodily fluids, feces, or environmental samples.

TriSilix can be produced at wafer-scale in a standard laboratory and exploits the intrinsic properties of the semiconductor Si which can be used as a resistive heating device and thermistor simultaneously. The sample solution can be maintained at a single, specific temperature (needed for isothermal amplification of NA such as recombinase-polymerase amplification (RPA) or cycled between different temperatures (with a precision of ± 1.3 °C) for PCR while the exact concentration of amplicons is measured quantitatively and in real-time electrochemically. Each lab-on-a-chip contains a DNA sensor, temperature detector and heater to automate the testing process. A typical smartphone battery could power up to 35 tests on a single charge.

The team performed qPCR analysis of genomic DNA extracted from clinical samples of Mycobacterium avium subspecies paratuberculosis (MAP) K10 strain. The lowest experimentally detectable concentration was 20 fg at the 35th cycle which is equivalent to detection of a single MAP bacterium in the sample. The team also performed qPCR analysis of the complimentary DNA (cDNA) of SARS-CoV-2, the causative agent of COVID-19. Using TriSilix, they were able detect 1 pg of cDNA of SARS-CoV-2 quantitatively, in real-time with specificity against a cDNA sequence from a similar virus (SARS-CoV), in as low as 20 cycles of PCR (lasting ~40 min). After 35 cycles, the difference in the electroanalytical signal was five times, showing clear separation.

Estefania Nunez-Bajo, PhD, a Chemical Engineer and first author of the study, said: “Monitoring infections at home could even help patients, with the help of their doctor, to personalize and tailor their antibiotic use to help reduce the growing problem of antibiotic resistance.” The study was published on December 2, 2020 in the journal Nature Communications.

Related Links:
Imperial College London


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.